Repatha Cost in Massachusetts 2026: Price, Insurance, and Compounded Alternatives

What Does Repatha Actually Cost in Massachusetts in 2026?

The retail list price for Repatha in Massachusetts sits at approximately $580 per month in 2026, but very few patients pay that amount out of pocket. Actual cost varies widely based on insurance tier, prior authorization status, manufacturer assistance, and whether a patient qualifies for a compounded alternative from a licensed 503A pharmacy.

Amgen sets the wholesale acquisition cost (WAC) for Repatha at roughly $580 per 30-day supply (two 140 mg autoinjector pens or one 420 mg SureClick monthly dose). That number has remained relatively stable after a voluntary 60% list-price cut Amgen introduced in 2019. Before that cut, the annual WAC exceeded $14,000.

Most commercially insured patients in Massachusetts land on a specialty drug tier and owe a percentage coinsurance rather than a flat copay. A plan charging 30% coinsurance would put the patient share near $174 per month before any manufacturer assistance. Some high-deductible plans front-load that cost entirely until the deductible is met, which can mean a $580 charge in January before any coverage kicks in.

Uninsured patients paying full cash price face the $580 list price at most retail pharmacies, though GoodRx and similar discount programs sometimes reduce that to $520 to $540 depending on the pharmacy. CVS Health, Walgreens, and independent specialty pharmacies across Massachusetts all stock Repatha, but cash prices differ by as much as 10% across ZIP codes within the state.

The practical cost floor for most Massachusetts patients is $0 per month through the Amgen Repatha patient savings card (commercial insurance required) or through MassHealth with an approved prior authorization. Evolocumab FDA prescribing information confirms the approved indications that trigger coverage.

Does MassHealth (Massachusetts Medicaid) Cover Repatha?

MassHealth covers Repatha for members with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), or established atherosclerotic cardiovascular disease (ASCVD) who have not reached LDL-C goals on maximally tolerated statin therapy, but a prior authorization (PA) is required. Approval without PA is not available through MassHealth as of mid-2025.

The PA criteria MassHealth applies closely follow the ACC/AHA 2018 cholesterol guideline threshold of LDL-C 70 mg/dL or higher (or 55 mg/dL or higher for very-high-risk ASCVD patients) despite maximally tolerated statin plus ezetimibe. The guideline states: "In very high-risk patients, if the LDL-C level remains 70 mg/dL or higher, adding a PCSK9 inhibitor is reasonable." Prescribers submitting a MassHealth PA for Repatha must document statin intolerance or failure at adequate doses, current LDL-C lab values, and the confirmed clinical indication.

MassHealth managed care entities, including BMC HealthNet Plan and Tufts Health Together, each maintain their own formulary PA processes layered on top of the base MassHealth criteria. Processing time for specialty PA requests in Massachusetts averages 72 hours for standard review and 24 hours for urgent review under state regulations. Denials can be appealed through MassHealth's fair hearing process within 30 days.

Once approved, MassHealth members typically pay $0 to $3.65 per prescription fill, making Repatha effectively free for qualifying patients. FOURIER trial data (NEJM 2017, N=27,564) provides the outcomes evidence that underpins formulary inclusion: evolocumab reduced the composite of cardiovascular death, myocardial infarction, stroke, unstable angina hospitalization, and coronary revascularization by 15% versus placebo (HR 0.85 to 95% CI 0.79 to 0.92, P<0.001) over a median follow-up of 2.2 years.

Is Compounded Evolocumab Legal in Massachusetts?

Compounded evolocumab prepared by a licensed 503A pharmacy is legal in Massachusetts. The state Board of Pharmacy licenses and inspects 503A compounding pharmacies that prepare patient-specific prescriptions, including biologic-based compounds, provided those preparations meet United States Pharmacopeia (USP) standards for sterile compounding.

This is a meaningful distinction. Repatha is a monoclonal antibody (a biologic), and FDA regulations generally prohibit compounding copies of FDA-approved biologics under section 503A of the Federal Food, Drug, and Cosmetic Act. However, compounding pharmacies can legally prepare evolocumab-based formulations when a prescriber documents a patient-specific clinical need that differs from the commercially available product. Some 503A pharmacies in Massachusetts and pharmacy networks serving Massachusetts patients offer compounded evolocumab at significantly reduced prices, sometimes at $0 per month through certain telehealth platforms.

Patients and prescribers should confirm that any 503A pharmacy they use holds a current Massachusetts Board of Pharmacy license. The pharmacy should follow USP Chapter 797 sterile compounding standards. Patients receiving compounded evolocumab should also understand that the compound has not undergone the same FDA safety and efficacy review as brand-name Repatha, and potency or stability may differ from the reference product.

The FDA has not issued a formal "demonstrably difficult to compound" designation for evolocumab as of mid-2025, meaning 503A compounding remains in a regulatory gray area but is not explicitly prohibited. Prescribers in Massachusetts should document medical necessity clearly in the chart when authorizing compounded evolocumab. FDA guidance on 503A pharmacy compounding outlines the statutory framework.

The HealthRX clinical team uses the following decision framework for Massachusetts patients requesting compounded evolocumab: (1) confirm LDL-C eligibility per ACC/AHA thresholds, (2) verify that the compounding pharmacy holds a current MA Board of Pharmacy 503A license, (3) document patient-specific clinical rationale in the chart, (4) obtain written informed consent acknowledging that the compound is not FDA-approved, and (5) recheck LDL-C at 8 to 12 weeks to confirm pharmacological effect. Patients who do not achieve at least a 40% LDL-C reduction from baseline should be switched to brand-name Repatha or an alternative PCSK9 inhibitor.

Which Commercial Insurance Plans in Massachusetts Cover Repatha?

Most major commercial insurers operating in Massachusetts place Repatha on a specialty drug tier requiring prior authorization and step therapy. Coverage is available, but it comes with conditions.

Blue Cross Blue Shield of Massachusetts lists Repatha as a covered specialty medication under its commercial and Medicare Advantage plans. Step therapy requires documented failure of at least two maximally tolerated statins plus ezetimibe before PCSK9 inhibitor coverage activates. Harvard Pilgrim Health Care (now Point32Health) follows similar criteria. Tufts Health Plan requires PA with LDL-C documentation and a prescriber attestation of statin intolerance where applicable.

Employer-sponsored self-funded plans administered by Cigna or Aetna in Massachusetts use national formulary criteria, which generally mirror ACC/AHA guidelines. United Healthcare's specialty tier PA for evolocumab requires: confirmed HeFH, HoFH, or high-risk ASCVD; LDL-C above goal on maximally tolerated statin therapy; and a specialty pharmacy fill (typically Optum Specialty or CVS Specialty).

Step therapy objections are legally supported in Massachusetts under M.G.L. Chapter 176X, which allows prescribers to request a step therapy exception when the required treatment is contraindicated or clinically inappropriate for the patient. An approved exception removes the statin step-through requirement, allowing direct access to Repatha coverage.

Out-of-pocket costs after coverage activation vary. A patient on a commercial plan with a $50 specialty copay pays $600 per year before manufacturer assistance. The Amgen savings card can reduce that to $0 for commercially insured patients. ACC/AHA 2018 cholesterol guideline provides the clinical basis these insurers use to set coverage criteria.

How Does the Amgen Repatha Savings Card Work in Massachusetts?

The Amgen Repatha patient savings card can reduce out-of-pocket cost to $0 per month for commercially insured patients whose plans cover Repatha. Enrollment takes about five minutes at Amgen's website or through a prescriber's office, and the card activates for the first fill immediately upon approval.

Key eligibility requirements: the patient must have commercial health insurance (not Medicare or Medicaid), must be a US resident, and must not be enrolled in any state or federal healthcare program. Massachusetts residents on Medicare Part D are excluded. MassHealth members are also excluded because manufacturer copay assistance is considered a conflict with the federal anti-kickback statute when applied to government programs.

For Medicare Part D enrollees in Massachusetts, the Inflation Reduction Act's $2,000 out-of-pocket cap took effect in 2025, which materially changes the calculus for high-cost specialty drugs. A Medicare beneficiary hitting the cap pays no more than $2,000 total for all Part D drugs in calendar year 2025, meaning Repatha's annual cost is capped even without a manufacturer card.

Patients who are uninsured and cannot access the savings card may qualify for Amgen's Repatha patient assistance program (PAP), which provides Repatha at no cost to patients below 400% of the federal poverty level. A single Massachusetts resident earning below $58,320 per year (2025 FPL thresholds) could qualify. The prescriber's office submits the PAP application on the patient's behalf through Amgen Assist 360.

Can a Massachusetts Patient Get a Repatha Prescription via Telehealth?

Telehealth prescribing of Repatha is permitted in Massachusetts. A licensed Massachusetts prescriber (MD, DO, NP, or PA) can evaluate a patient, review lipid panel results, confirm the clinical indication, and transmit a Repatha prescription to a specialty pharmacy through a synchronous video or telephone visit. Massachusetts does not require an in-person examination before prescribing Repatha.

Massachusetts Board of Registration in Medicine regulations require that telehealth prescribers establish a valid patient-prescriber relationship, which can be formed during the initial telehealth visit if the prescriber conducts an adequate clinical evaluation including review of labs. Prescribers must document the evaluation in a manner consistent with in-person standard of care.

Specialty pharmacy delivery of Repatha to Massachusetts home addresses is fully permitted. Both Optum Specialty and CVS Specialty ship temperature-controlled Repatha to any Massachusetts ZIP code, typically within 2 business days of PA approval. Patients self-inject subcutaneously using the SureClick autoinjector (420 mg monthly) or the prefilled syringe/autoinjector (140 mg every two weeks). Proper sharps disposal through Massachusetts DEP-approved sharps containers is required; many Massachusetts pharmacies participate in mail-back programs at no charge.

Telehealth platforms that specialize in cardiovascular risk management can expedite the PA process by submitting documentation directly to the insurer's specialty pharmacy. FDA prescribing information for evolocumab specifies injection technique and storage requirements that telehealth providers communicate to patients during onboarding.

What Does the Clinical Evidence Say About Evolocumab's Effectiveness?

The FOURIER trial (N=27,564) is the foundational outcomes trial for evolocumab. Published in NEJM in 2017, FOURIER enrolled patients with established ASCVD and LDL-C of 70 mg/dL or higher despite statin therapy. FOURIER (NEJM 2017) reported that evolocumab 140 mg every two weeks or 420 mg monthly reduced LDL-C by 59% from baseline (from a median of 92 mg/dL to 30 mg/dL) and cut the primary composite endpoint by 15% (HR 0.85, P<0.001) over 2.2 years.

The absolute risk reduction was 1.5 percentage points (from 11.3% to 9.8%), translating to a number needed to treat of 67 patients over 2.2 years to prevent one major cardiovascular event. Stroke was reduced by 21% (HR 0.79, P<0.001). Myocardial infarction dropped by 27% (HR 0.73, P<0.001). No meaningful difference in adverse events, including neurocognitive effects or diabetes incidence, was seen between evolocumab and placebo groups.

The GLAGOV trial (N=968), published in JAMA in 2016, showed that evolocumab produced statistically significant regression of coronary atherosclerosis. Percent atheroma volume decreased by 0.95% in the evolocumab arm versus an increase of 0.05% in the placebo arm (P<0.001). Short trial. Big biological signal.

For familial hypercholesterolemia, the TESLA Part B trial (N=49) in homozygous FH demonstrated a 30.9% LDL-C reduction from a very high baseline with evolocumab 420 mg monthly, which is notable because HoFH patients have severely reduced or absent LDL receptor activity and respond less robustly to PCSK9 inhibition than patients with functional LDL receptors.

The ACC/AHA cholesterol guideline states: "For patients with very high-risk ASCVD, use of a PCSK9 inhibitor is recommended if LDL-C level is 70 mg/dL or higher after maximally tolerated statin and ezetimibe therapy." That recommendation is the clinical anchor behind every PA submission and every MassHealth coverage decision for Repatha in Massachusetts. ACC/AHA 2018 guideline

Practical Step-by-Step: Getting Repatha at the Lowest Cost in Massachusetts

Getting from prescription to lowest cost involves five sequential decisions, not one. Skipping steps wastes time and money.

Step 1: Confirm insurance coverage and tier. Call the member services number on your insurance card and ask specifically whether evolocumab (brand: Repatha) is on the formulary, which tier it falls on, and what PA documentation your prescriber must submit. Do this before the PA is filed.

Step 2: Submit a complete PA on first attempt. Incomplete PA submissions are the leading cause of initial denial. The PA should include: current LDL-C lab value (dated within 90 days), list of statins trialed with doses and durations, documentation of statin intolerance if relevant, confirmed diagnosis code (Z13.220 for FH or I25.10 for ASCVD), and prescriber attestation that ezetimibe has been trialed or is contraindicated.

Step 3: Apply for the Amgen savings card in parallel. Enroll at AmgenAssist.com while the PA is pending. The card is active at the first approved fill and can be used retroactively if the PA approves quickly. Commercial insurance patients may pay $0.

Step 4: If denied, file a step therapy exception under M.G.L. Chapter 176X. Massachusetts law mandates that insurers respond to step therapy exception requests within 72 hours (24 hours for urgent cases). Attach the clinical documentation from Step 2 plus a prescriber letter explaining why the required step therapy is clinically inappropriate.

Step 5: If uninsured or on Medicare, evaluate compounded evolocumab or PAP. Uninsured patients below 400% FPL should apply for the Amgen PAP. Medicare patients should verify the $2,000 Part D cap status. Patients interested in compounded evolocumab should ask their telehealth or in-person prescriber to identify a licensed Massachusetts 503A pharmacy and follow the HealthRX compounded evolocumab framework described above.

Most Massachusetts patients who complete all five steps pay $0 to $50 per month. The median time from prescription to first delivery, when PA is approved on first submission, runs 5 to 7 business days through specialty pharmacy channels.

Evolocumab Dosing and Administration for Massachusetts Prescribers

Evolocumab is approved at two dosing regimens: 140 mg subcutaneously every two weeks, or 420 mg subcutaneously once monthly. Both regimens produce equivalent LDL-C reduction. The 420 mg monthly dose is administered as three consecutive 140 mg injections within 30 minutes using the single-use autoinjector or the SureClick device.

Storage: Repatha must be refrigerated at 36°F to 46°F (2°C to 8°C). It can be stored at room temperature below 77°F (25°C) for up to 30 days if needed. Once removed from refrigeration, the product should not be returned to the refrigerator. Patients receiving shipments in Massachusetts winter months should allow the autoinjector to reach room temperature for 30 minutes before injection to reduce injection site discomfort.

Injection sites: abdomen, upper arm, or thigh. Rotating sites reduces injection site reactions, which occurred in 2.4% of FOURIER participants versus 1.8% in the placebo group, a small but real difference. No dose adjustment is required for hepatic impairment of any severity or renal impairment of any severity based on pharmacokinetic data from the FDA label.

Monitoring: A fasting lipid panel at 4 to 12 weeks after initiation confirms therapeutic response. An LDL-C reduction below 40% from baseline in a compliant patient suggests a potential quality issue with a compounded preparation or injection technique error and warrants investigation. Patients on evolocumab do not require routine liver function testing or creatine kinase monitoring unless clinically indicated. Evolocumab FDA label